Cargando…

Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder

BACKGROUND: We evaluated the orexin receptor antagonist filorexant (MK-6096) for treatment augmentation in patients with major depressive disorder. METHODS: We conducted a 6-week, double-blind, placebo-controlled, parallel-group, Phase II, proof-of-concept study. Patients with major depressive disor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Connor, Kathryn M, Ceesay, Paulette, Hutzelmann, Jill, Snavely, Duane, Krystal, Andrew D, Trivedi, Madhukar H, Thase, Michael, Lines, Christopher, Herring, W Joseph, Michelson, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5570043/ https://www.ncbi.nlm.nih.gov/pubmed/28582570 http://dx.doi.org/10.1093/ijnp/pyx033

Ejemplares similares

A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia
por: Connor, Kathryn M., et al.
Publicado: (2016)

Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial
por: Herring, W. Joseph, et al.
Publicado: (2020)

BAY-6096: A Potent, Selective, and Highly Water-Soluble Adrenergic α(2B) Antagonist
por: Meibom, Daniel, et al.
Publicado: (2023)

Orexin, orexin receptor antagonists and central cardiovascular control
por: Carrive, Pascal
Publicado: (2013)

Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease
por: Voss, Tiffini, et al.
Publicado: (2018)

Opportunities and perspectives for developing orexin receptor antagonists
por: Steiner, Michel A., et al.
Publicado: (2014)

Orexin receptor antagonists as therapeutic agents for insomnia
por: Equihua, Ana C., et al.
Publicado: (2013)

Orexin antagonists for neuropsychiatric disease: progress and potential pitfalls
por: Yeoh, Jiann Wei, et al.
Publicado: (2014)

Suvorexant: The first orexin receptor antagonist to treat insomnia
por: Dubey, Ashok K., et al.
Publicado: (2015)

Pharmacological or genetic orexin1 receptor inhibition attenuates MK-801 induced glutamate release in mouse cortex
por: Aluisio, Leah, et al.
Publicado: (2014)

Kinetic properties of “dual” orexin receptor antagonists at OX(1)R and OX(2)R orexin receptors
por: Callander, Gabrielle E., et al.
Publicado: (2013)

Orexin-1 and orexin-2 receptor antagonists reduce ethanol self-administration in high-drinking rodent models
por: Anderson, Rachel I., et al.
Publicado: (2014)

Functional Magnetic Resonance Imaging Reveals Different Neural Substrates for the Effects of Orexin-1 and Orexin-2 Receptor Antagonists
por: Gozzi, Alessandro, et al.
Publicado: (2011)

The clinical efficacy of orexin antagonists for primary insomnia- A review of the evidence
por: Vasiliu, O.
Publicado: (2023)

Orexin 1 receptor antagonists in compulsive behavior and anxiety: possible therapeutic use
por: Merlo Pich, Emilio, et al.
Publicado: (2014)

The hypocretin/orexin antagonist almorexant promotes sleep without impairment of performance in rats
por: Morairty, Stephen R., et al.
Publicado: (2014)

Formulation development for the orexin receptor antagonist almorexant: assessment in two clinical studies
por: Dingemanse, Jasper, et al.
Publicado: (2014)

Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment
por: Berger, Benjamin, et al.
Publicado: (2021)

Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist
por: Krause, Andreas, et al.
Publicado: (2022)

The effect of the CGRP receptor antagonist (MK-8825) on the response to trigeminal nociception in rodents
por: Romero-Reyes, M, et al.
Publicado: (2013)

PET Imaging of GPR44 by Antagonist [(11)C]MK-7246 in Pigs
por: Cheung, Pierre, et al.
Publicado: (2021)

Intact learning and memory in rats following treatment with the dual orexin receptor antagonist almorexant
por: Dietrich, Hendrik, et al.
Publicado: (2010)

Novel class of medications, orexin receptor antagonists, in the treatment of insomnia – critical appraisal of suvorexant
por: Norman, Jessica L, et al.
Publicado: (2016)

Effects of the dual orexin receptor antagonist DORA-22 on sleep in 5XFAD mice
por: Duncan, Marilyn J., et al.
Publicado: (2019)

The dual orexin receptor antagonist TCS1102 does not affect reinstatement of nicotine-seeking
por: Khoo, Shaun Yon-Seng, et al.
Publicado: (2017)

Neuropeptide Y-Induced Orexigenic Action Is Attenuated by the Orexin Receptor Antagonist in Bullfrog Larvae
por: Matsuda, Kouhei, et al.
Publicado: (2017)

Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia
por: Roch, Catherine, et al.
Publicado: (2021)

Evidence‐based insomnia treatment strategy using novel orexin antagonists: A review
por: Kishi, Taro, et al.
Publicado: (2021)

Synthesis and biological activity evaluation of azacycloheptane sulfonamide derivatives as potential orexin receptor antagonists
por: Guo, Bin, et al.
Publicado: (2020)

Effect of a dual orexin receptor antagonist on Alzheimer's disease: Sleep disorders and cognition
por: Zhou, Mengzhen, et al.
Publicado: (2023)

Daridorexant, a Recently Approved Dual Orexin Receptor Antagonists (DORA) in Treatment of Insomnia
por: Sarathi Chakraborty, Dwaipayan, et al.
Publicado: (2023)

Dual orexin receptor antagonists for the treatment of insomnia: systematic review and network meta-analysis
por: Rocha, Rebeka Bustamante, et al.
Publicado: (2023)

Effect of the glucocorticoid receptor antagonist RU486 on MK-801 induced behavioural sensitisation
por: Lefevre, Emilia M., et al.
Publicado: (2017)

Functional cardiac orexin receptors: role of orexin-B/orexin 2 receptor in myocardial protection
por: Patel, Vanlata H., et al.
Publicado: (2018)

Orexin Receptor Antagonism, a New Sleep-Enabling Paradigm: A Proof-of-Concept Clinical Trial
por: Hoever, P, et al.
Publicado: (2012)

Dissociating orexin-dependent and -independent functions of orexin neurons using novel Orexin-Flp knock-in mice
por: Chowdhury, Srikanta, et al.
Publicado: (2019)

LSN2424100: a novel, potent orexin-2 receptor antagonist with selectivity over orexin-1 receptors and activity in an animal model predictive of antidepressant-like efficacy
por: Fitch, Thomas E., et al.
Publicado: (2014)

Differential sleep-promoting effects of dual orexin receptor antagonists and GABA(A) receptor modulators
por: Gotter, Anthony L, et al.
Publicado: (2014)

Inhibition of ghrelin-induced feeding in rats by pretreatment with a novel dual orexin receptor antagonist
por: So, Mariko, et al.
Publicado: (2017)

Orexin Receptor Competitive Antagonists: A Novel target of the Sedative and hypnotics drugs for the pharmacotherapy of Insomnia
por: Banerjee, Indrajit
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_a8488f4lqki66fntma8bkt5kmf